Spago Nanomedical
0.11 SEK
-3.86 %
Less than 1K followers
SPAGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Spago Nanomedical
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.3 | 0.7 | 1.1 | 1.2 | 1.9 | 0.4 |
| growth-% | 1,040.0 % | 93.0 % | 59.1 % | 14.3 % | 59.2 % | -77.1 % | |
| EBITDA | -19.9 | -18.6 | -38.8 | -39.1 | -43.4 | -33.4 | -26.8 |
| EBIT | -20.2 | -19.0 | -39.2 | -39.5 | -43.1 | -33.7 | -26.9 |
| Profit before taxes | -20.2 | -18.9 | -39.1 | -39.2 | -42.2 | -32.5 | -26.6 |
| Net income | -20.2 | -18.9 | -39.1 | -39.2 | -42.2 | -32.5 | -26.6 |
| EPS | -0.61 | -0.40 | -0.66 | -0.08 | -0.30 | -0.08 | -0.07 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -66,180.0 % | -5,438.6 % | -5,881.2 % | -3,724.8 % | -3,612.5 % | -1,748.7 % | -6,127.5 % |
| EBIT-% | -67,370.0 % | -5,544.4 % | -5,938.2 % | -3,759.0 % | -3,589.2 % | -1,764.9 % | -6,165.7 % |
| ROE | -14.7 % | -11.9 % | -21.1 % | -19.9 % | -102.2 % | -97.8 % | -86.4 % |
| ROI | -14.4 % | -11.6 % | -20.4 % | -19.0 % | -79.7 % | -82.1 % | -72.4 % |